{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:32:02Z","timestamp":1697689922967},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,1,7]],"date-time":"2013-01-07T00:00:00Z","timestamp":1357516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metabolism of triazole antifungal agents is highly competitive to conventional post\u2010transplant immunosuppressants like cyclosporine A (CsA) via the cytochrome P450\u2010dependent pathway. We present the first report on lethal complications that may arise due to this type of drug interaction. A retrospective survey identified 10 of 104 cases (9.62%) that suffered life\u2010threatening complications associated with the interaction between CsA and itraconazole or voriconazole following allogeneic hematopoietic stem cell transplantation (allo\u2010HSCT) at our center. According to the close drug monitoring, all 10 patients experienced supratherapeutic levels of CsA even with a preemptive CsA dosage reduction and prompt dose adjustment. Six patients developed grade I to III acute graft\u2010versus\u2010host disease (<jats:styled-content style=\"fixed-case\">aGVHD<\/jats:styled-content>) and eventually died from either idiopathic pneumonia syndrome or diffuse alveolar hemorrhage; another four patients died from CSA\u2010associated neurological complications. Impaired hepatic and renal function was noted in only one of these 10 cases. The high frequency as well as the unpredictability of severe complications lead us to suggest that triazole should always be replaced by another antifungal medication (e.g., amphotericin B or Echincandins) while patients receive CsA after HSCT, especially in the Chinese population.<\/jats:p>","DOI":"10.1111\/ctr.12070","type":"journal-article","created":{"date-parts":[[2013,1,7]],"date-time":"2013-01-07T14:04:46Z","timestamp":1357567486000},"page":"255-260","source":"Crossref","is-referenced-by-count":4,"title":["Adverse drug interactions as a high\u2010risk factor for lethal post\u2010transplant complications in <scp>C<\/scp>hinese population"],"prefix":"10.1111","volume":"27","author":[{"given":"Ting","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Hematology Fujian Institute of Hematology Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue Mei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Qiang","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan Hui","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematology Fujian Institute of Hematology Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian Da","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology Fujian Institute of Hematology Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Yun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology Fujian Institute of Hematology Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Feng","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology Fujian Institute of Hematology Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao Hong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Hematology Fujian Institute of Hematology Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru Ling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology Fujian Institute of Hematology Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi Zhe","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology Fujian Institute of Hematology Union Hospital of Fujian Medical University Fuzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_2_6_3_1","unstructured":"Pfizer Inc. Vfend (voriconazole) package insert.New York NY 2008."},{"key":"e_1_2_6_4_1","unstructured":"Janssen Pharmaceutica Products. Sporanox (itraconazole capsules) package insert.Titusville NJ 2000."},{"key":"e_1_2_6_5_1","unstructured":"Janssen Pharmaceutica Products. Sporanox (itraconazole oral solution) package insert.Titusville NJ 2000."},{"key":"e_1_2_6_6_1","unstructured":"Janssen Pharmaceutica Products. Sporanox (itraconazole injection) package insert.Titusville NJ 2000."},{"key":"e_1_2_6_7_1","first-page":"825","article-title":"1994 consensus conference on aGVHD grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/516480"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1496"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0456"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-9-200305060-00006"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80126-1"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.254"},{"key":"e_1_2_6_15_1","first-page":"261","article-title":"Pretransplantation conditioning influence on the occurrence of cyclosporine or FK\u2010506 neurotoxicity in allogeneic bone marrow transplantation","volume":"25","author":"Bartynski WS","year":"2004","journal-title":"AJNR Am J Neuroradiol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241120-00002"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fctr.12070","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.12070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T14:48:08Z","timestamp":1697640488000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.12070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,7]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/ctr.12070"],"URL":"https:\/\/doi.org\/10.1111\/ctr.12070","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,7]]}}}